Vera Therapeutics Provides Business Update and Reports Third Quarter 2026 Financial Results
Vera Therapeutics, Inc. (VERA) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Vera Therapeutics Provides Business Update and Reports Third Quarter 2026 Financial Results • TRUTAKNA® (atacicept-vymj) U.S. launch building early momentum following July 7 accelerated approval by the U.S. Food and Drug Administration (FDA) with approximately 700 Pa
How this was made
The 30-second read
Why it matters
The earnings release provides fresh financial metrics and regulatory milestones that were not previously public.
Market read
First‑time earnings disclosure with new revenue and loss figures, plus a supplemental BLA filing, offers actionable insight for traders.
What to watch
Cash runway remains strong with $384M cash and $75M debt draw, reducing near‑term liquidity concerns.
TRUTAKNA launch generated $10.3 million of net product revenue in Q3, while commercial-launch investment and operating cash use increased.
The first quarter of TRUTAKNA revenue and approximately 700 Patient Start Forms establish early launch activity, but the company reported a $93.7 million net loss, $305.9 million of nine-month operating cash use, and a substantial increase in selling, general and administrative expense tied to commercialization.
Key metrics
shortened, hover for the filing’s print| Metric | Value | q/q | y/y |
|---|---|---|---|
| Product revenue, net, three months ended September 30, 2026GAAP | $10.28M | – | – |
| Cost of sales, three months ended September 30, 2026GAAP | $3.30M | – | – |
| Research and development, three months ended September 30, 2026GAAP | $41.25M | – | – |
| Selling, general and administrative, three months ended September 30, 2026GAAP | $61.43M | – | – |
| Total operating expenses, three months ended September 30, 2026GAAP | $106.0M | – | – |
| Loss from operations, three months ended September 30, 2026GAAP | −$95.70M | – | – |
| Other income, net, three months ended September 30, 2026GAAP | $1.99M | – | – |
| Net loss, three months ended September 30, 2026GAAP | −$93.71M | – | – |
| Change in unrealized gain/loss on marketable securities, three months ended September 30, 2026GAAP | −$301K | – | – |
| Comprehensive loss, three months ended September 30, 2026GAAP | −$94.01M | – | – |
| Net loss per share attributable to common stockholders, basic and diluted, three months ended September 30, 2026GAAP | $ (1.30) | – | – |
| Weighted-average shares used in computing net loss per share attributable to common stockholders, basic and diluted, three months ended September 30, 2026GAAP | 72,126,588 | – | – |
| Product revenue, net, nine months ended September 30, 2026GAAP | $10.28M | – | – |
| Cost of sales, nine months ended September 30, 2026GAAP | $3.30M | – | – |
| Research and development, nine months ended September 30, 2026GAAP | $187.3M | – | – |
| Selling, general and administrative, nine months ended September 30, 2026GAAP | $153.0M | – | – |
| Total operating expenses, nine months ended September 30, 2026GAAP | $343.6M | – | – |
| Loss from operations, nine months ended September 30, 2026GAAP | −$333.3M | – | – |
| Other income, net, nine months ended September 30, 2026GAAP | $9.11M | – | – |
| Net loss, nine months ended September 30, 2026GAAP | −$324.2M | – | – |
| Change in unrealized gain/loss on marketable securities, nine months ended September 30, 2026GAAP | −$1.49M | – | – |
| Comprehensive loss, nine months ended September 30, 2026GAAP | −$325.7M | – | – |
| Net loss per share attributable to common stockholders, basic and diluted, nine months ended September 30, 2026GAAP | $ (4.51) | – | – |
| Weighted-average shares used in computing net loss per share attributable to common stockholders, basic and diluted, nine months ended September 30, 2026GAAP | 71,816,111 | – | – |
| Net cash used in operating activities, nine months ended September 30, 2026GAAP | $305.9M | – | – |
| Cash, cash equivalents and marketable securities, as of September 30, 2026GAAP | $384.0M | – | – |
| Long-term debt, as of September 30, 2026GAAP | $75.43M | – | – |
Amounts quoted below without a unit are in thousands, as in the filing’s tables. Per-share figures are as printed.
mid-2027 and Q1 2027 outlook
- NotePotential full approval of TRUTAKNA in adults with primary IgAN, subject to FDA review of the sBLA, expected in mid-2027.
- NotePlanned Marketing Authorisation Application submission to the European Medicines Agency expected in Q1 2027 for standard marketing authorisation.
What drove it
- TRUTAKNA received FDA accelerated approval on July 7, 2026 and generated $10.3 million of net product revenue in Q3.
- The company received approximately 700 Patient Start Forms to date following TRUTAKNA’s accelerated approval.
- Research and development expense decreased primarily because manufacturing costs for TRUTAKNA commercial supply have been capitalized as inventory since accelerated approval.
- Selling, general and administrative expense reflected investment in the commercial launch of TRUTAKNA.
- Through 104 weeks, the annualized eGFR slope was -0.6 mL/min/1.73m²/year with TRUTAKNA compared with -5.6 mL/min/1.73m²/year with placebo, a treatment difference of 5.0 mL/min/1.73m²/year (p<0.0001).
Concerns
- TRUTAKNA remains approved under accelerated approval, and continued approval may be contingent upon verification and description of clinical benefit in a confirmatory clinical trial.
- Net loss was $93.7 million for the quarter ended September 30, 2026.
- Net cash used in operating activities was $305.9 million for the nine months ended September 30, 2026.
- Payer coverage policies and market acceptance are identified risks for the commercial launch.
- Additional borrowing capacity is subject to satisfaction of certain conditions.
What to watch
- Potential FDA full approval of TRUTAKNA in adults with primary IgAN, expected in mid-2027 subject to FDA review of the sBLA.
- Planned Marketing Authorisation Application submission to the European Medicines Agency expected in Q1 2027.
- TRUTAKNA patient access, payer coverage policies, and additional Patient Start Forms following launch.
- Commercial-launch spending and operating cash use.
- Continued investigation of atacicept in antibody-mediated glomerular diseases through the PIONEER basket trial.
Balance sheet and cash flow
- Cash, cash equivalents and marketable securities were $384.0 million as of September 30, 2026.
- Cash, cash equivalents and marketable securities were $ 714,589 (in thousands) as of December 31, 2025.
- In late October, the Company drew $75 million under its debt facility.
- On a pro forma basis, adjusting solely to reflect the October borrowing as if it had occurred on September 30, the Company’s balance of cash, cash equivalents, and marketable securities would have been $459 million.
- As of today, up to $350 million remain available under its debt facility, subject to satisfaction of certain conditions.
- Net cash used in operating activities during the nine months ended September 30, 2026 was $305.9 million, compared to $171.1 million for the nine months ended September 30, 2025.
Analysis
Vera’s first reported quarter of TRUTAKNA commercialization produced $10.3 million of net product revenue following the July 7, 2026 accelerated approval. Management reported approximately 700 Patient Start Forms to date and described growing interest from the IgAN community. The commercial trajectory will depend on access and payer coverage policies, which management said are still taking shape.
The income statement reflects the transition to commercialization. Research and development expense was $41.3 million versus $56.5 million in the prior-year quarter, primarily because commercial-supply manufacturing costs that had been classified in research and development have been capitalized as inventory since approval. Selling, general and administrative expense was $61.4 million versus $27.5 million, reflecting launch investment. Cost of sales was $3.3 million, and the company reported a $93.7 million net loss, or $1.30 per share.
Cash use remains a central consideration. Net cash used in operating activities was $305.9 million for the nine months ended September 30, 2026, compared with $171.1 million in the prior-year period. Cash, cash equivalents, and marketable securities were $384.0 million at September 30. The company subsequently drew $75 million under its debt facility, resulting in pro forma cash, cash equivalents, and marketable securities of $459 million, while up to $350 million remained available subject to conditions.
Clinical and regulatory activity supports the launch narrative. ORIGIN 3 final efficacy results showed an annualized eGFR slope of -0.6 mL/min/1.73m²/year with TRUTAKNA versus -5.6 mL/min/1.73m²/year with placebo through 104 weeks. Vera completed its sBLA submission on November 3, 2026 for full approval in adults with primary IgAN and expects a potential FDA decision in mid-2027, subject to FDA review. The company also expects to submit a European Marketing Authorisation Application in Q1 2027.
The reported period establishes initial demand but does not include financial revenue or expense guidance. The key reported trade-off is between building the TRUTAKNA launch and funding that investment, as higher selling, general and administrative expense and operating cash use accompanied the initial revenue contribution. Continued approval under the accelerated-approval indication may be contingent upon verification and description of clinical benefit in a confirmatory clinical trial.
Management, verbatim
We are excited by the early momentum of the TRUTAKNA launch, which exemplifies our long-standing confidence in its potential to become a foundational therapy in IgAN. Our transition to a commercial-stage company marks a new chapter for Vera, as we deliver on our commitment to people living with IgAN.
Marshall Fordyce, M.D., Founder and Chief Executive Officer of Vera Therapeutics
Our team is executing on the launch priorities we established for TRUTAKNA, with growing interest from the IgAN community and approximately 700 PSFs received since launch. We are encouraged by the payer coverage policies taking shape. Our focus remains on expanding access and ensuring nephrologists have the tools and education they need to help eligible patients begin treatment with TRUTAKNA.
Matt Skelton, Chief Commercial Officer of Vera Therapeutics
Not in the filing
stated, not guessed- Prior-quarter financial comparisons for third-quarter 2026 metrics were not reported.
- Gross profit and gross margin were not reported.
- Free cash flow was not reported.
- Quarterly operating cash flow was not reported.
- Non-GAAP financial measures were not reported.
- Share repurchases and dividends were not reported.
- Financial revenue, gross-margin, operating-expense, or tax-rate guidance was not reported.
- Prior outlook was not provided, so comparison with prior guidance is unavailable.
Written by an AI language model from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure is checked against the filing text, and a metric the filing does not print, or whose value, prior period and change do not add up, is dropped from the metrics. The model can still misread a table, in the metrics or in the text, so check a number in the filing before you rely on it. Consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.
Background
Vera Therapeutics filed a Form 8‑K reporting its Q3 2026 results, product launch progress, and regulatory filing updates.
Ticker impact
Q3 2026 earnings release with $10.3M product revenue, $93.7M net loss and sBLA submission for full FDA approval.
potential downside as investors weigh larger loss against modest revenue and pending approval risk
The new financials provide fresh data; the loss exceeds prior period while revenue is modest, and the sBLA outcome remains uncertain, likely pressuring the stock.
Market effects
Highlights progress in the rare‑disease kidney‑therapy space, may boost peer biotech sentiment.
Limited to US biotech sector; no broader regional effect.
Minimal global impact beyond niche biotech investors.
Counterpoint
The approval pipeline could accelerate revenue growth, making the loss a short‑term issue.
Key entities
- companyVera Therapeutics, Inc.
Commercial‑stage biotech developing TRUTAKNA for IgA nephropathy.
